Merrimack Pharmaceuticals, Inc. (MACK)
| Market Cap | 86.23M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.97M |
| Shares Out | 13.41M |
| EPS (ttm) | -0.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | $1.50 |
| Dividend Yield | 23.28% |
| Trading Day | June 11 |
| Last Price | $6.43 |
| Previous Close | $6.41 |
| Change ($) | 0.02 |
| Change (%) | 0.31% |
| Day's Open | 6.41 |
| Day's Range | 6.37 - 6.48 |
| Day's Volume | 10,707 |
| 52-Week Range | 3.07 - 9.45 |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Full Year 2020 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals Q3 2020 Earnings Release
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Second Quarter 2020 Financial Results
Merrimack Pharmaceuticals: SCLC Presents A Lower Hurdle For Approval Than Initially Assumed
Merrimack Pharmaceuticals - A Better Way To Invest In Biotechnology
Merrimack Pharmaceuticals is a special-situations investment.
Merrimack Pharmaceuticals Inc. has announced that it will be discontinuing one of its cancer drugs, as well as conducting layoffs.
About MACK
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was founded in 1993 and is headquartered in Cambridge, Massachusetts.
| Industry Biotechnology | IPO Date Mar 29, 2012 |
| Stock Exchange NASDAQ | Ticker Symbol MACK |
Analyst Forecasts
The average 12-month stock price forecast for MACK is 4.00, which is a decrease of -37.79% from the latest price.